drugset
drugset / Trial / NCT03826641

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects

NCT03826641 ↗

Phase 1 Completed 85 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HCP1801 in healthy subjects.

Timeline

Start
2019-02-01
Primary completion
2019-03-25
Completion
2019-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg —
Subject Metformin Small molecule 1000 mg —

Indications

No indication recorded.